Milas L - Search Results

1

Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.

Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Sano D, et al. Among authors: milas l. Clin Cancer Res. 2011 Apr 1;17(7):1815-27. doi: 10.1158/1078-0432.CCR-10-2120. Epub 2011 Feb 24. Clin Cancer Res. 2011. PMID: 21350000 Free PMC article.

2

Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.

Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Mason KA, et al. Among authors: milas l. Clin Cancer Res. 2005 Jan 1;11(1):361-9. Clin Cancer Res. 2005. PMID: 15671567

3

130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.

Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz TA, Milas L, Mason KA. Wiedenmann N, et al. Among authors: milas l. Clin Cancer Res. 2007 Mar 15;13(6):1868-74. doi: 10.1158/1078-0432.CCR-06-2534. Clin Cancer Res. 2007. PMID: 17363543

4

Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.

Sano D, Berlin JM, Pham TT, Marcano DC, Valdecanas DR, Zhou G, Milas L, Myers JN, Tour JM. Sano D, et al. Among authors: milas l. ACS Nano. 2012 Mar 27;6(3):2497-505. doi: 10.1021/nn204885f. Epub 2012 Feb 16. ACS Nano. 2012. PMID: 22316245 Free PMC article.

5

CpG oligodeoxynucleotide enhances tumor response to radiation.

Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK. Milas L, et al. Cancer Res. 2004 Aug 1;64(15):5074-7. doi: 10.1158/0008-5472.CAN-04-0926. Cancer Res. 2004. PMID: 15289307

6

Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.

Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA, Milas L. Raju U, et al. Among authors: milas l. Radiother Oncol. 2006 Aug;80(2):185-91. doi: 10.1016/j.radonc.2006.07.027. Epub 2006 Aug 14. Radiother Oncol. 2006. PMID: 16905211

7

INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

Mason KA, Valdecanas D, Hunter NR, Milas L. Mason KA, et al. Among authors: milas l. Invest New Drugs. 2008 Feb;26(1):1-5. doi: 10.1007/s10637-007-9072-5. Epub 2007 Jul 13. Invest New Drugs. 2008. PMID: 17628743

8

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.

Riesterer O, Matsumoto F, Wang L, Pickett J, Molkentine D, Giri U, Milas L, Raju U. Riesterer O, et al. Among authors: milas l. Invest New Drugs. 2011 Jun;29(3):514-22. doi: 10.1007/s10637-009-9361-2. Epub 2009 Dec 22. Invest New Drugs. 2011. PMID: 20024691

9

Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.

Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U. Cho H, et al. Among authors: milas l. Anticancer Res. 2009 Nov;29(11):4409-15. Anticancer Res. 2009. PMID: 20032386 Free article.

10

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.

Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK. Torres MA, et al. Among authors: milas l. Invest New Drugs. 2011 Aug;29(4):554-61. doi: 10.1007/s10637-010-9389-3. Epub 2010 Feb 2. Invest New Drugs. 2011. PMID: 20119866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

316 results

Search Page

Filters